Genfit stock falls over 5% and breaks its support at €11.56
The Lille-based biopharma company is experiencing a sharp setback at the start of the week, despite the stock having posted several positive catalysts in recent weeks. The decline occurs against a backdrop of a broadly bullish European market, making the correction all the more visible.
A marked decline that pushes the stock below its short and medium-term moving averages
Genfit falls 5.36% to €10.94 in trading, marking one of the sharpest declines on the SBF 120, in an index that is nonetheless up 0.76%. The move erases the last closing price at €11.56, which was precisely the support threshold identified for the stock. The price now stands clearly below the 20-day moving averages (€13.36, representing a -18.1% gap) and the 50-day moving average (€13.51, a -19% gap), two benchmarks that act as a technical ceiling weighing on any rebound attempt.
Only the 200-day MA at €9.29 remains below the current price, confirming that the long-term trend remains bullish despite recent turbulence. The RSI at 36 is approaching oversold territory without having reached it, reflecting ongoing selling exhaustion without an immediate reversal signal. The seven-day performance is now down nearly 16%, and 22.4% over one month, a correction that contrasts with the gain of over 200% recorded over one year.
Fundamentals in development, short positions gaining traction
The correction comes on the heels of a dense period of news for the group. Genfit's entry into the CAC Mid 60 and SBF 120 indices, effective after the close on Friday, September 18, 2026, had constituted a major institutional recognition. Earlier, the company had announced its intention to test nangibotide in acute decompensation of cirrhosis, a new indication that enriches its pipeline following the acquisition of this candidate during the summer of 2026. On the operational front, during the publication of Q1 2026 results on May 21, 2026, the momentum of royalties linked to Iqirvo had been presented as a favorable driver for financial margins. In this context, the rapid increase in short positions warrants attention: according to recorded disclosures, two funds cumulate 1.04% of capital sold short, up 1.04 percentage points over thirty days.
This level remains modest in absolute terms, but the recent acceleration indicates that certain institutional investors are positioning themselves against the stock's rise, or seeking to hedge an existing exposure. This point merits monitoring over time without drawing hasty conclusions about the price direction. The resistance level at €14.52 now represents the first hurdle to overcome for the long-term bullish trend to regain credibility in the short term.
